Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Neurol 106:e214864, Dhivagaran,T.,et al, 2026
GLP-1s:Novo Nordisk and Eli Lilly Face Laswsuit Over Vision Loss andw Eye Damage
BMJ 395:e101099, Cozzolino,A., 2026
Idiopathic Intracranial Hypertension
NEJM 393:1409-1414, Horton,J.C., 2025
Glucagon-Like Peptide-1 Receptor Agonists and Wernicke Encephalopathy:A Pharmacovigilance Study and Literature Review
Clin Nutr 57:106571, Lev,D.,et al, 2026
Allodynia and Dysethesia Associated with Semaglutide and Tirzepatide
Cureus 17:94126, Ahern,S., 2026
Neurological Complications Associated with Rapid Weight Loss and Nutritional Deficiencies Following GLP-1 Agonist Use:A Case Report
BMC Neurol 26:5, Zahir,A.,et al, 2026
Peripheral Nerve Complications From Medications Utilised for Weight Loss:A Systematic Review
J Neurol 273:503, OGorman,C.,et al, 2026
GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies
Neurol 105:e213916, Triplett,J.D.,et al, 2025
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
JAMA Neurol 82:887-892, Sioutas,G.S.,et al, 2025
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
NEJM 391:1193-1205, Malhotra,A.,et al, 2024